LONDON, February 16 /PRNewswire/ -- From 1st January Grünenthal further builds its pain management portfolio with Tramacet(R) (paracetamol 325mg/tramadol 37.5mg). Tramacet joins Zydol (tramadol) and Versatis (lidocaine 5% medicated plaster) in Grünenthal UK's pain portfolio. Tramacet was launched in the UK in 2004. Grünenthal UK will promote Tramacet from January 2009, initially in partnership with Janssen-Cilag Ltd. who are the current Marketing Authorisation Holders. The product licence and Marketing Authorisation is scheduled to transfer to Grünenthal in mid 2009. Until this time, Janssen-Cilag Ltd. will continue to be responsible for all legal and regulatory aspects and continue a full medical information and pharmacovigilance service.

BARCELONA, February 16 /PRNewswire/ --

- GSMA Mobile World Congress Barcelona

Finland-based ICT and automation solution provider Sesca has introduced a smartphone application stack called Sesca Ample which is based on open source application development framework Qt. Sesca Ample offers a groundbreaking mobile phone operating system featuring best-of-class user experience and state-of-the-art applications.

BARCELONA, Spain, February 16 /PRNewswire/ --

- New product is designed to open the mobile Web opportunity to small businesses around the world.

MOBILE WORLD CONGRESS -- dotMobi, a worldwide leader in the development discovery of quality mobile content and the company behind the .mobi Internet domain, today announced the global availability of Instant Mobilizer(TM), a service that brings small-to-medium businesses (SMBs) around the world in touch with their customer base quickly and affordably through the mobile Web without any development effort.

LONDON, February 16 /PRNewswire/ --

- Frost Sullivan to Host Quarterly Analyst Briefing on the European Cardiac Rhythm Management Market on Wednesday 25 February 2009

The Healthcare Group at Frost Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Cardiac Rhythm Management Market to be held on Wednesday, 25 February, 2009 at 4 p.m. GMT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

HELSINKI, February 16 /PRNewswire/ --

- Valimo Demonstrates how to Apply Mobile Authentication With OpenID to Sign in to Your Favourite Online Services

Valimo, the global market leader in mobile ID solutions, introduces mobile authentication for OpenID. OpenID authentication eliminates the need for multiple usernames across different websites. Combining Valimo Mobile ID with OpenID technology creates more convenient and secure identification service on mobile phones. First deployment of OpenID mobile authentication is already available from the Turkish service Sifreyok, provided by Pozitron.

FRANKFURT, Germany, February 16 /PRNewswire/ -- For the second time leading German chemical parks and sites will jointly showcase their work at an ACHEMA exhibition. Under the theme Make it in Germany: Your Prime Chemical Location in Europe they will be presenting from May 11-15 at ACHEMA 2009 in Hall 9.2, Stand B35-E36.

BARCELONA, February 16 /PRNewswire/ --

- Real Named Master Music Service Provider

Today from GSMA Mobile World Congress 2009, SK Telecom and RealNetworks(R), Inc., (RNWK) the digital entertainment services company, announced that they have deepened their strategic relationship in mobile entertainment services. Real, which has provided music-related ASP services to SK Telecom since 2001, will extend its existing contracts with the mobile operator, and begin providing new services, both through 2011. It has also taken a minority stake in SK Telecom's Korean subsidiary LoEn to develop and market digital music offerings.

STUTTGART, Germany and VIENNA, Austria, February 16 /PRNewswire/ -- The world-wide leading online gaming provider, bwin Interactive Entertainment AG, implements the 3rd EU Money Laundering Directive using the S/Monitor software from Cellent Finance Solutions AG. bwin is one of the first industry players to exercise the stipulated extended due diligence in screening customer data for suspected terrorism or embargo breaches.

Last night at two in the morning I woke to find someone had grafted a zombie arm to my left shoulder. I commanded it to move—no response. I jabbed it with my right hand—no response. I threw it against the wall—no response. Would this limb remain forever zombific? Medical literature is conflicted.

The current guidelines for tourniquet use suggest a one-hour maximum for restricted blood flow to upper extremities and a two-hour maximum for lower extremities, but also admit that the onset and degree of tissue death (necrosis) varies according to patient age and physical condition. Past these thresholds, restricted blood flow can result in nerve damage. (The tingling you feel is your nerves’ way of expressing angst—a call to roll over before they get really pissed.)